MCYRMontgomery County Young Republicans
References in periodicals archive ?
These results indicated that the overall rate of MCyR was 49% including 62% of patients harboring the T315I mutation [34].
(15) These responses were durable, with MCyR maintained in 90% of dasatinib responders compared with 74% of imatinib responders.
NAF is number of forecasts issued in June of McYR (I-B-E-S Summary Data).
In patients with chronic phase CML, efficacy was determined by the number of patients who experienced a major cytogenetic response (MCyR) within the first 24 weeks of treatment.